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Abstract: The 1858T allele in the protein tyrosine phosphatase non-receptor type 22 (PTPN22)
locus shows one of the strongest and most consistent genetic associations with autoimmune
diseases. We synthesized all meta-analyses reporting a genetic association of the PTPN22 1858T
C/T polymorphism with autoimmune diseases. This work examined their validity to discover
false positive results under Bayesian methods. We conducted a PubMed search to identify
relevant publications and extracted the respective results, published until 30 November 2018.
In observational studies, the associations of 1858 C/T genetic variant were noteworthy for 12
autoimmune or autoimmunity-related diseases (rheumatoid arthritis, systemic lupus erythematosus,
type 1 diabetes mellitus, juvenile idiopathic arthritis, Crohn’s disease, anti-neutrophil cytoplasmic
antibody (ANCA)-associated vasculitis, vitiligo, Graves’ disease, myasthenia gravis, Addison’s
disease, giant cell arteritis, and endometriosis). In contrast, we could not confirm the noteworthiness
for eight diseases (systemic sclerosis, psoriasis, Behçet’s disease, autoimmune thyroid disease,
alopecia areata, Sjögren’s syndrome, inflammatory bowel disease, and ankylosing spondylitis). From
the meta-analysis of genome-wide association studies (GWAS) with a p-value < 5 × 10−8, findings
verified noteworthiness for all autoimmune diseases (psoriatic arthritis, myasthenia gravis, juvenile
idiopathic arthritis and rheumatoid arthritis). The results from meta-analysis of GWAS showing
a p-value ranging between 0.05 and 5 × 10−8 were noteworthy under both Bayesian approaches
(ANCA-associated vasculitis, type 1 diabetes mellitus, giant cell arteritis and juvenile idiopathic
arthritis). Re-analysis of observational studies and GWAS by Bayesian approaches revealed the
noteworthiness of all significant associations observed by GWAS, but noteworthiness could not be
confirmed for all associations found in observational studies.
Keywords: autoimmune disease; single nucleotide polymorphism; PTPN22; false-positive report
probability; Bayesian false discovery probability; genome wide association study; meta-analysis
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1. Introduction
The 1858T allele in the protein tyrosine phosphatase non-receptor type 22 (PTPN22) locus has a
strong and consistent genetic association with autoimmune diseases. This phosphatase is expressed in
hematopoietic cells and in immune cells with highest levels found in neutrophils and natural killer
cells [1]. The PTPN22 gene is located on chromosome 1p 13.3–13.1 and encodes the cytoplasmic
lymphoid specific phosphatase (Lyp) [2].
Many single nucleotide polymorphisms (SNPs) have been identified in PTPN22, but only one
non-synonymous SNP has been intensively studied in relation to autoimmune diseases. The SNP
rs2476601 is a change of cytosine to thymidine at nucleotide 1858 (C1858T) which results in an amino
acid change from arginine to tryptophan at codon 620 (R620W). This codon is located in the polyproline
binding motif P1 [2,3]. The amino acid substitution is located in the polyproline motif within the
Lyp protein and, thus, is thought to be involved in binding to SH3 domains during protein–protein
interactions [4]. Lyp interacts with C-terminal Src kinase (Csk) to regulate both B-cell receptor (BCR)
and T-cell receptor (TCR) signaling [5,6]. It has been suggested that 1858 C/T polymorphism increases
Lyp protein activity resulting in inhibition of T-cell signaling and a failure to delete autoreactive
T-cells during thymic selection. Since 1858 C/T polymorphism results in immune responses against
autoantigens [3], genetic association is proposed to be restricted to disorders that have a strong
autoantibody component.
There is no consensus whether 1858 C/T polymorphism is a gain- or loss-of-function variant.
The C1858T has been reported as a susceptibility locus associated with several autoimmune diseases.
It was first reported in type 1 diabetes mellitus (T1DM) [2]. Numerous studies have confirmed this
association [7,8], and implication of the PTPN22 1858 C/T polymorphism was also proposed in
other autoimmune diseases [8]. While implicated in the genetic basis of autoimmunity, the 1858 C/T
polymorphism may protect individuals from environmental pathogens [9].
In recent years, the advent of new genotyping and other molecular biology technologies
has provided a huge increase in the quantities of data available for analysis. In epidemiology,
candidate-gene and genome-wide association identified a large number of genes associated with
diseases. Therefore, a general focus has been laid on the way genetic associations are reported.
Meta-analysis has been widely used as a powerful approach to identify true-positive associated genes,
but several limitations can alter the results. In most cases, results between overlapping meta-analyses
on the same topic are inconsistent because of several confounding factors such as inclusion and
exclusion criteria and number of included studies.
In addition, since the prior probabilities of genetic associations are low, there is a possibility
that the number of false-positive associations by chance may be high, which could lead to an
increased likelihood of finding false-positive associations. In the present study, we used Bayesian
approaches [10–12] because they represent a more powerful tool than other methods for detecting true
noteworthiness (true associations) for the genetic associations between the gene variant and disease.
Bayesian approaches depend not only on the observed P value but also on both the prior probability
that the association between the genetic variant and the disease is real (genuine) and the statistical
power of the test [10]. Although a strict p-value of <5 × 10−8 was set to determine the statistical
significance in genome-wide association studies (GWAS) or its meta-analysis, a significance level of
observational studies on genetic epidemiology (p-value of <5 × 10−8) has not been changed. Therefore,
judging the true significance between the suggested gene variant and disease is very important and
Bayesian approaches can detect the claimed associations are genuine (true or false), which would be
the reason why noteworthiness is so important. Bayesian approaches allow researchers to consider a
much broader class of conceptual and mathematical models and permit to work on complex analytical
problems, irrespective of the size of data [10–12].
In this review, we have synthesized all available data reporting the association of the PTPN22
1858 C/T polymorphism with autoimmunity retrieved from meta-analyses. Both meta-analyses of
observational studies and GWAS were included and Bayesian approaches have been employed to
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estimate the noteworthiness of the evidence. We aimed to provide an overview to interpret the
reported significant findings and discuss the genetic association of autoimmunity with the PTPN22
1858 C/T polymorphism.
2. Methods
2.1. Inclusion and Exclusion Criteria
Studies were included if they satisfied the following criteria: (1) estimated the risk conferred
by PTPN22 in autoimmune diseases using meta-analyses which reported odds ratio (OR) and 95%
confidence interval (CI), and (2) published in English.
Articles were excluded if (1) they did not report PTPN22 1858C/T polymorphism or autoimmune
or autoimmunity-related diseases, (2) did not perform meta-analysis and (3) the original study did not
report upper and lower confidence intervals, because these are necessary to calculate false-positive
report probability (FPRP) and Bayesian false discovery probability (BFDP) (1 from observational
studies and 7 from meta-analyses of GWAS, Supplementary Tables S1 and S2). The eligible
studies were selected according to the standardized reporting protocol of systematic reviews and
meta-analyses PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses)
checklist (Supplementary Table S3).
2.2. Search Strategy
A PubMed search was performed to extract data from meta-analyses regarding the PTPN22
1858C/T polymorphism in autoimmune or autoimmunity-related diseases published until 30
November 2018. We used the search terms “PTPN22” AND “polymorphism” AND “meta”. Out of 86
yielded articles, 17 articles were excluded after screening the title and abstract. Full text screening led
to the exclusion of another 6 articles. Additional 10 meta-analyses were excluded because they did not
report significant associations or lower and upper limits of the confidence interval. From a total of
53 eligible studies, 46 were meta-analyses of observational studies and 7 studies were meta-analyses of
GWAS [Supplemental references] (Figure 1).
2.3. Data Extraction
We classified 53 articles into two categories depending on the methods of the respective studies,
either meta-analysis of observational studies or GWAS. Data were extracted from each article, including
the type of autoimmune disease, clinical symptoms, genetic variant, genotype comparison, odds ratio
(OR), 95% confidence interval (CI), p-value, statistical model used for analysis (i.e., either random or
fixed), ethnicity of participants, the number of cases and controls, heterogeneity described with I2 or
p-value and publication bias assessed as Egger’s p-value [13].
The reported associations were significant if the p-value was lower than 0.05, equally described
as 95% CI excluding 1.0 in meta-analyses of observational studies (Tables 1–7) and 5 × 10−8 in
meta-analyses of the GWAS (Table 8). Genotypic and allelic comparisons from GWAS with a p-value
between 0.05 and 5 × 10−8 had a borderline significance and were separately organized in Table 9.
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Table 1. Meta-analysis results of associations between rheumatoid arthritis (RA) and the PTPN22 1858 C/T polymorphism from observational studies.
Author, Year No. of
Studies
Comparison OR (95% CI) p-Value Model Disease Ethnicity I2 (%)
Egger’s
p-Value
Power
OR
1.2
Power
OR
1.5
FPRP Values at Prior Probability
BFDP
0.001
BFDP
0.000001OR 1.2 OR 1.5
0.001 0.000001 0.001 0.000001
Nabi G, 2016 [1S] 35 TT vs. CC+CT 2.6 (2.273–3.089) <0.0001 F RA Caucasian 0 >0.05 NA NA NA NA NA NA 0.000 0.000
Nabi G, 2016 [1S] 8 T vs. C 1.22 (0.99–1.496) 0.061 F RA Asian 31.16 >0.05 0.447 0.976 0.993 1.000 0.985 1.000 0.998 1.000
Elshazli R, 2015 [2S] 29 CT+TT vs. CC 1.79 (1.604–2.006) <0.001 R RA Overallmixed 60.34 0.038 0.000 0.017 0.000 0.065 0.000 0.000 0.000 0.000
Elshazli R, 2015 [2S] 18 CT+TT vs. CC 1.68 (1.579–1.793) <0.001 F RA European 14.05 0.141 NA NA NA NA NA NA 0.000 0.000
Elshazli R, 2015 [2S] 3 T vs. C 3.68 (1.020–13.312) 0.047 R RA African 86.51 0.627 0.006 0.085 0.999 1.000 0.998 1.000 0.999 1.000
Elshazli R, 2015 [2S] 2 T vs. C 3.57 (1.534–8.323) 0.003 F RA Asian 7.10 - 0.006 0.022 0.998 1.000 0.993 1.000 0.998 1.000
Tang GP, 2014 [3S] 32 T vs. C 1.61 (1.518–1.69) <0.001 NA RA Overallmixed NA - NA NA NA NA NA NA 0.000 0.000
Tang GP, 2014 [3S] - T vs. C 1.612 (1.54–1.68) <0.001 NA RA Caucasian NA - NA NA NA NA NA NA 0.000 0.000
Song GG, 2013 [4S] 30 T vs. C 1.49 (1.332–1.668) <1.0 × 10−9 R RA Overallmixed 71.9 - 0.000 0.546 0.000 0.048 0.000 0.000 0.000 0.001
Song GG, 2013 [4S] 24 T vs. C 1.423 (1.260–1.605) 1.0 × 10−8 R RA European 72.6 - 0.003 0.805 0.003 0.770 0.000 0.011 0.001 0.477
Song GG, 2013 [4S] 7 T vs. C 1.561 (1.373–1.775) <1.0 × 10−9 F RA (RF+ vs.RF−)
Overall
mixed 34.6 - 0.000 0.272 0.000 0.266 0.000 0.000 0.000 0.003
Song GG, 2013 [4S] 6 CT+TT vs. CC 2.02 (1.721–2.371) <1.0 × 10−9 F RA Non-European 44.9 - NA NA NA NA NA NA 0.000 0.000
Zheng J, 2012 [5S] 36 T vs. C 1.65 (1.58–1.71) <1.0 × 10−16 - RA Overallmixed - - NA NA NA NA NA NA 0.000 0.000
Zheng J, 2012 [5S] 11 T vs. C 1.63 (0.51–1.75) <1.0 × 10−16 - RF+ Overallmixed - - NA NA NA NA NA NA 0.000 0.000
Zheng J, 2012 [5S] 11 T vs. C 1.35 (1.22–1.49) 9.04 × 10−9 - RF- Overallmixed - - 0.010 0.982 0.000 0.206 0.000 0.003 0.000 0.180
Zheng J, 2012 [5S] 11 T vs. C 1.78 (1.59–2.01) <1.0 × 10−16 - RA (anti-CCP+) Overallmixed - - NA NA NA NA NA NA 0.000 0.000
Lee YH, 2012 [6S] 18 T vs. C 1.64 (1.51–1.77) <0.001 R RA Overallmixed 32.6 0.482 NA NA NA NA NA NA 0.000 0.000
Lee YH, 2012 [6S] 13 T vs. C 1.59 (1.486–1.69) <0.001 F RA European 0.00 0.111 NA NA NA NA NA NA 0.000 0.000
Lee YH, 2012 [6S] 5 CT +TT vs. CC 1.81 (1.28–2.56) <0.001 R RA Non-European 61.3 0.647 0.011 0.146 0.988 1,000 0.855 1.000 0.984 1.000
Lee YH, 2012 [6S] 6 - 1.64 (1.44–1.87) <0.001 F RF+ vs. RF- Overallmixed 0.00 0.24 0.000 0.095 0.000 0.088 0.000 0.000 0.000 0.000
Jiang Y, 2012 [7S] 34 TT vs. CC+TC 2.54 (2.17–2.98) <1.0 × 10−15 F RA Overallmixed 0.00 - NA NA NA NA NA NA 0.000 0.000
Jiang Y, 2012 [7S] 10 T vs. C 1.67 (1.51–1.85) <1.0 × 10−15 F RF+ Overallmixed 0.00 - NA NA NA NA NA NA 0.000 0.000
Ramirez M, 2012 [8S] 2 T vs. C 1.90 (1.34–2.68) 3.0 × 10−4 F RA Overallmixed - - 0.004 0.089 0.983 1.000 0.741 1.000 0.969 1.000
Nong LM, 2011 [9S] 19 TT vs. CC 2.86 (2.29–3.57) <0.01 - RA European 13.0 - NA NA NA NA NA NA 0.000 0.000
Nong LM, 2011 [9S] 6 TT vs. CC 4.49 (2.88–7.00) <0.01 - RF+ European 1.7 - 0.000 0.000 0.922 1.000 0.049 0.981 0.058 0.984
Nong LM, 2011 [9S] 6 TT vs. CC 2.86 (2.29–3.57) <0.01 - RF- European 13.0 - NA NA NA NA NA NA 0.000 0.000
Nong LM, 2011 [9S] 19 T vs. C 1.54 (1.47–1.62) <0.01 - RA Overallmixed 26,2 0.421 NA NA NA NA NA NA 0.000 0.000
Nong LM, 2011 [9S] - T vs. C 1.70 (1.52–1.89) <0.01 - RF+ Overallmixed 0.00 >0.05 NA NA NA NA NA NA 0.000 0.000
Nong LM, 2011 [9S] - T vs. C 1.37 (1.18–1.59) <0.01 - RF- Overallmixed 45.3 >0.05 0.041 0.884 0.457 0.999 0.037 0.975 0.601 0.999
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Table 1. Cont.
Author, Year No. of
Studies
Comparison OR (95% CI) p-Value Model Disease Ethnicity I2 (%)
Egger’s
p-Value
Power
OR
1.2
Power
OR
1.5
FPRP Values at Prior Probability
BFDP
0.001
BFDP
0.000001OR 1.2 OR 1.5
0.001 0.000001 0.001 0.000001
Totaro MC, 2011
[10S] 24 T vs. C 1.79 (1.60–2.01) <0.05 R RA
Overall
mixed 79.42 0.46 NA NA NA NA NA NA 0.000 0.000
Totaro MC, 2011
[10S] 23 T vs. C 1.80 (1.61–2.02) <0.05 R RA
Without
Italian 79.42 - NA NA NA NA NA NA 0.000 0.000
Totaro MC, 2011
[10S] 14 T vs. C 2.01 (1.67–2.43) <0.05 R
RA
(miao)(Quality
score >11)
Overall
mixed 61.14 - 0.000 0.001 0.011 0.918 0.000 0.000 0.000 0.001
Plant P, 2010 [11S] 20 T vs. C 1.60 (1.53–1.67) 2.30 × 10−98 R RA Overallmixed 59.9 - NA NA NA NA NA NA 0.000 0.000
Plant P, 2010 [11S] 2 T vs. C 1.48 (1.33–1.66) 6.25 × 10−12 R RA Caucasian,European >50 - 0.000 0.591 0.000 0.112 0.000 0.000 0.000 0.004
Curtin K, 2007 [12S] 2 CC vs. CT+TT 2.53 (1.32–4.84) <0.001 - RA Overallmixed NA NA 0.012 0.057 0.998 1.000 0.989 1.000 0.997 1.000
Curtin K, 2007 [12S] 2 CC vs. CT+TT 2.13 (1.76–2.57) <0.001 - RF+ Overallmixed NA NA 0.000 0.000 0.003 0.731 0.000 0.000 0.000 0.000
Curtin K, 2007 [12S] 2 CC vs. CT+TT 1.90 (1.55–2.34) <0.001 - RA (CCP+) Overallmixed NA NA 0.000 0.013 0.168 0.995 0.000 0.106 0.001 0.542
Curtin K, 2007 [12S] 2 CC vs. CT+TT 1.47 (1.15–1.88) 0.001 - RA (CCP-) Overallmixed NA NA 0.053 0.564 0.976 1.000 0.792 1.000 0.984 1.000
Lee YH, 2007 [13S] 12 TT vs. CT+CC 2.89 (2.19–3.82) <0.00001 - RA Overallmixed 0.00 - 0.000 0.000 0.212 0.996 0.000 0.042 0.000 0.011
RA, rheumatoid arthritis; RF+, rheumatoid factor positive; RF−, rheumatoid factor negative; CCP+, cyclic citrullinated peptide positive; CCP−, cyclic citrullinated peptide negative; OR,
odds ratio; CI, confidence interval; R, random; F, fixed; S, Supplementary; FPRP, false-positive report probability; BFDP, Bayesian false discovery probability. Each comparison of genetic
associations was regarded as noteworthy when FPRP of <0.2 or BFDP of <0.8 or both are fulfilled and the values were bolded when the results are significant by FPRP or BFDP. NAs are
expressed when information is not available by FPRP calculations.
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Table 2. Meta-analysis results of associations between juvenile idiopathic arthritis (JIA) and the PTPN22 1858 C/T polymorphism from observational studies.
Author, Year No. of
Studies
Comparison OR (95% CI) p-Value Model Disease Ethnicity I2 (%)
Egger’s
p-Value
Power
OR
1.2
Power
OR
1.5
FPRP Values at Prior Probability
BFDP
0.001
BFDP
0.000001OR 1.2 OR 1.5
0.001 0.000001 0.001 0.000001
DI Y, 2015 [14S] 7 T vs. C 1.38 (1.04–1.83) 0.025 R JIA (cases n < 500) Overall mixed 72.4 0.619 0.166 0.719 0.993 1.000 0.972 1.000 0.997 1.000
DI Y, 2015 [14S] 4 T vs. C 1.55 (1.39–1.72) <0.001 R JIA (cases n ≥ 500) Overall mixed 8.00 0.309 0.000 0.300 0.000 0.000 0.000 0.000 0.000 0.000
DI Y, 2015 [14S] 8 T vs. C 1.52 (1.32–1.76) <0.001 R JIA(population-based) Overall mixed 55.5 0.979 0.001 0.430 0.027 0.965 0.000 0.048 0.003 0.738
DI Y, 2015 [14S] 3 T vs. C 1.36 (1.15–1.60) <0.001 R JIA(hospital-based) Overall mixed 8.80 0.882 0.066 0.881 0.761 1.000 0.191 0.996 0.878 1.000
DI Y, 2015 [14S] 4 T vs. C 1.52 (1.32–1.78) <0.001 F JIA American 45.7 0.585 0.002 0.435 0.108 0.992 0.000 0.317 0.022 0.957
DI Y, 2015 [14S] 6 T vs. C 1.36 (1.01–1.83) 0.041 R JIA Augean 74.4 0.555 0.204 0.741 0.995 1.000 0.983 1.000 0.998 1.000
DI Y, 2015 [14S] 11 T vs. C 1.42 (1.20–1.68) <0.001 R JIA Overall mixed 61.6 0.303 0.025 0.739 0.636 0.999 0.056 0.983 0.676 1.000
DI Y, 2015 [14S] 9 T vs. C 1.48 (1.36–1.62) <0.001 F JIA (Adjusted) Overall mixed 8.8 0.268 NA NA NA NA NA NA 0.000 0.000
Kaalla M, 2013 [15S] 8 T vs. C 1.44 (1.31, 1.60) <0.0001 F RA Overall mixed - - 0.000 0.776 0.000 0.033 0.000 0.000 0.000 0.002
Kaalla M, 2013 [15S] T vs. C 2.05 (1.37, 3.77) <0.0005 - RF+ Overall mixed - - 0.042 0.157 0.998 1.000 0.993 1.000 0.998 1.000
Kaalla M, 2013 [15S] T vs. C 1.56 (1.21, 2.02) 0.0007 - RF− Overall mixed - - 0.023 0.383 0.970 1.000 0.660 0.999 0.970 1.000
Kaalla M, 2013 [15S] T vs. C 1.45 (1.18, 1.79) <0.0005 - RA (Oligoarticular) Overall mixed - - 0.039 0.624 0.933 1.000 0.466 0.999 0.951 1.000
Zheng J, 2012 [5S] 7 T vs. C 1.54 (1.40–1.70) 1.0 × 10−16 - JIA Overall mixed - - NA NA NA NA NA NA 0.000 0.000
Lee YH, 2012[16S] 7 T vs. C 1.311(1.205–1.427) <1.8 × 10
−8 - JIA European 32.2 0.353 0.020 0.999 0.000 0.019 0.000 0.000 0.000 0.033
Lee YH, 2007 [13S] 2 TT vs. CC 1.89 (1.09–3.29) 0.02 - JIA Overall mixed 0.00 - 0.054 0.207 0.998 1.000 0.992 1.000 0.998 1.000
JIA, juvenile idiopathic arthritis; OR, odds ratio; R, random; F, fixed; S, supplementary; FPRP, false-positive report probability; BFDP, Bayesian false discovery probability. Each comparison
of genetic associations was regarded as noteworthy when FPRP of <0.2 or BFDP of <0.8 or both are fulfilled and the values were bolded when the results are significant by FPRP or BFDP.
NAs are expressed when information is not available by FPRP calculations.
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Table 3. Meta-analysis results of associations between systemic lupus erythematosus (SLE) and the PTPN22 1858 C/T polymorphism from observational studies.
Author, Year No. of
Studies
Comparison OR (95% CI) p-Value Model Disease Ethnicity I2 (%)
Egger’s
p-Value
Power
OR
1.2
Power
OR
1.5
FPRP Values at Prior Probability
BFDP
0.001
BFDP
0.000001OR 1.2 OR 1.5
0.001 0.000001 0.001 0.000001
Hu LY, 2017 [17S] 17 TT+CT vs.CC 1.53 (1.346–1.742) 9.17 × 10
−11 R SLE Overall mixed 44.2 0.05 0.000 0.378 0.001 0.481 0.000 0.000 0.000 0.019
Hu LY, 2017 [17S] 4 T vs. C 2.56 (1.796–3.665) 2.219 × 10−7 F SLE American 0.00 >0.05 0.000 0.002 0.938 1.000 0.122 0.993 0.438 0.999
Hu LY, 2017 [17S] 11 T vs. C 1.39 (1.261–1.552) 2.153 × 10−10 F SLE European 32.8 0.938 0.002 0.906 0.000 0.108 0.000 0.000 0.000 0.025
Hu LY, 2017 [17S] 2 TT+CT vs.CC
5.08
(2.053–12.569) 4.315 × 10
−4 F SLE African 0.00 >0.05 0.001 0.004 0.998 1.000 0.991 1.000 0.997 1.000
de Lima SC, 2017 [18S] 19 T vs. C 1.54 (1.38–1.72) 0.000 F SLE Overall mixed - - 0.000 0.320 0.000 0.004 0.000 0.000 0.000 0.000
de Lima SC, 2017 [18S] NA T vs. C 1.47 (1.29–1.66) 0.0000 F SLE Caucasian 13.96 - 0.001 0.628 0.001 0.495 0.000 0.001 0.000 0.067
de Lima SC, 2017 [18S] NA T vs. C 2.41 (1.68–3.44) 0.0000 F SLE Latin 0.000 - 0.000 0.005 0.954 1.000 0.219 0.996 0.667 1.000
Shi L, 2013 [19S] 4 T vs. C 2.33 (1.78–3.04) <0.00001 F SLE Overall mixed 0.00 <0.05 0.000 0.001 0.475 0.999 0.001 0.438 0.002 0.698
Shi L, 2013[19S] 4 TC vs.CC+TT 2.33 (1.78–3.04) < 0.00001 F SLE Overall mixed 0.00 - 0.000 0.001 0.475 0.999 0.001 0.438 0.002 0.698
Lea WW, 2011 [20S] 11 T vs. C 1.56 (1.34–1.822) 2.0× 10−8 R SLE Overall mixed 49.3 0.405 0.000 0.310 0.041 0.977 0.000 0.060 0.003 0.750
Zheng J, 2012 [5S] 14 T vs. C 1.46 (1.31–1.62 7.33 × 10−13 - SLE Overall mixed - - 0.000 0.695 0.000 0.009 0.000 0.000 0.000 0.000
Ramirez M, 2012 [8S] 2 T vs. C 2.65 (0.74–4.05) 1.0 × 10−5 F SLE Overall mixed NA - 0.000 0.004 0.982 1.000 0.610 0.999 0.916 1.000
Lea WW, 2011 [20S] 7 T vs. C 1.49 (1.28–1.735) 2.8 × 10−8 R SLE European 46.5 0.908 0.003 0.534 0.096 0.991 0.001 0.346 0.027 0.965
Lea WW, 2011 [20S] 3 T vs. C 2.35 (1.644–3.373) 2.9 × 10−6 F SLE Hispanic 0.00 0.639 0.000 0.007 0.962 1.000 0.300 0.998 0.769 1.000
Lee YH, 2007 [13S] 5 CT vs. CC 1.41 (1.22–1.63) <0.00001 - SLE Overall mixed 0.00 - 0.015 0.799 0.189 0.996 0.004 0.810 0.172 0.995
SLE, systemic lupus erythematosus; OR, odds ratio; R, random; F, fixed; S, supplementary; FPRP, false-positive report probability; BFDP, Bayesian false discovery probability. Each
comparison of genetic associations was regarded as noteworthy when FPRP of <0.2 or BFDP of <0.8 or both are fulfilled and the values were bolded when the results are significant by
FPRP or BFDP.
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Table 4. Meta-analysis results of associations between vasculitides and the PTPN22 1858 C/T polymorphism from observational studies.
Author, Year No. of
Studies
Comparison OR (95% CI) p-Value Model Disease Ethnicity I2 (%)
Egger’s
p-Value
Power
OR
1.2
Power
OR
1.5
FPRP Values at Prior Probability
BFDP
0.001
BFDP
0.000001OR 1.2 OR 1.5
0.001 0.000001 0.001 0.000001
ANCA-associated vasculitis
Rahmattulla, 2015
[21S] 4
CT +TT vs.
CC 1.39 (1.24–1.56) <0.001 R
ANCA-associated
vasculitis
Overall
mixed 0.00 - 0.006 0.902 0.004 0.780 0.000 0.024 0.002 0.654
Cao Y, 2015 [22S] 4 A vs. G 1.44 (1.26–1.64) 2.27 × 10−5 F ANCA Whitepopulation 0.00 >0.05 0.003 0.731 0.013 0.929 0.000 0.051 0.004 0.788
Cao Y, 2015 [22S] 3 A vs. G 1.72 (1.35–2.20) 1.25 × 10−7 F GPA Whitepopulation 0.00 >0.05 0.002 0.138 0.883 1.000 0.102 0.991 0.679 1.000
Cao Y, 2015 [22S] 2 A vs. G 1.53 (1.08–2.15) 0.02 F MPA Whitepopulation 0.00 >0.05 0.081 0.455 0.994 1.000 0.969 1.000 0.996 1.000
Cao Y, 2015 [22S] 2 A vs. G 1.74 (1.25–2.43) 0.001 F ANCA(miao)(with proteinase 3)
White
population 0.00 >0.05 0.015 0.192 0.987 1.000 0.857 1.000 0.985 1.000
Cao Y, 2015 [22S] 2 A vs. G 1.94 (0.64–5.85) 0.24 R ANCA(miao)(myeloperoxidase)
White
population 77 >0.05 0.197 0.324 0.999 1.000 0.999 1.000 0.999 1.000
Lee YH, 2012 [23S] 2 T vs. C 2.04 (1.53–2.719) 1.02 × 10−6 F ANCA+WG Caucasian 0 NA 0.000 0.017 0.882 1.000 0.056 0.983 0.375 0.998
Lee YH, 2012 [23S] 2 T vs. C 3.43 (1.18–10.36) 0.029 F ANCA+ vs.ANCA
Overall
mixed 0 NA 0.031 0.071 0.999 1.000 0.998 1.000 0.999 1.000
Lee YH, 2012 [23S] 3 T vs. C 1.41 (1.23–1.63 1.59 × 10−6 F AAV Caucasian 0.00 0.481 0.011 0.791 0.119 0.993 0.002 0.656 0.091 0.990
Lee YH, 2012 [23S] 2 T vs. C 1.83 (1.37–2.43) 3.09 × 10−5 F WG Caucasian 0 NA 0.002 0.086 0.945 1.000 0.271 0.997 0.841 1.000
Zheng J, 2012 [5S] 2 T vs. C 1.45 (1.24–1.69) 3.07 × 10−6 - ANCA-associated(miao)vasculitis
Overall
mixed - - 0.008 0.668 0.204 0.996 0.003 0.748 0.125 0.993
Giant cell arteritis
Lester S, 2016 [24S] 7 T vs. C 1.33 (1.16–1.52) 3.0 × 10−5 R GCA Overallmixed 4.72 - 0.066 0.961 0.302 0.998 0.029 0.967 0.541 0.999
Lester S, 2016 [24S] 5 T vs. C 1.21 (1.03–1.43) <0.05 R GCA NorthernEuropean - - 0.461 0.994 0.982 1.000 0.962 1.000 0.997 1.000
Lester S, 2016 [24S] 2 T vs. C 1.56 (1.28–1.91) <0.05 R GCA SouthernEuropean - - 0.006 0.352 0.750 1.000 0.045 0.979 0.572 0.999
ANCA, anti-neutrophil cytoplasmic antibody; AAV, ANCA-associated vasculitis; WG, Wegener’s granulomatosis; GCA, giant cell arteritis; GPA, granulomatosis with polyangiitis; MPA,
microscopic polyangiitis; OR, odds ratio; R, random; F, fixed; S, supplementary; FPRP, false-positive report probability; BFDP, Bayesian false discovery probability. Each comparison of
genetic associations was regarded as noteworthy when FPRP of <0.2 or BFDP of <0.8 or both are fulfilled and the values were bolded when the results are significant by FPRP or BFDP.
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Table 5. Meta-analysis results of associations between other rheumatic diseases and the PTPN22 1858 C/T polymorphism from observational studies.
Author, Year No. of
Studies
Comparison OR (95% CI) p-Value Model Disease Ethnicity I2 (%)
Egger’s
p-Value
Power
OR
1.2
Power
OR
1.5
FPRP Values at Prior Probability
BFDP
0.001
BFDP
0.000001OR 1.2 OR 1.5
0.001 0.000001 0.001 0.000001
Systemic sclerosis
Zheng J, 2012 [5S] 11 T vs. C 1.16 (1.02–1.31) 0.015 - SSc Overall mixed - - 0.708 1.000 0.959 1.000 0.944 1.000 0.996 1.000
Zheng J, 2012 [5S] 11 T vs. C 1.25 (1.03–1.54) 0.037 - ATA+SSc Overall mixed - - 0.351 0.957 0.990 1.000 0.974 1.000 0.997 1.000
Zheng J, 2012 [5S] 11 T vs. C 1.16 (1.00–1.33) 0.019 - ATA-SSc Overall mixed - - 0.686 1.000 0.980 1.000 0.971 1.000 0.998 1.000
Diaz-Gallo LM, 2011
[25S] 9 T vs. C 1.15 (1.03–1.28) 0.03 F SSc Overall mixed 33.8 - 0.782 1.000 0.931 1.000 0.913 1.000 0.995 1.000
Diaz-Gallo LM, 2011
[25S] 9 T vs. C 1.22 (1.05–1.42) 0.02 F SSc(ACA+) Overall mixed 0.0 - 0.416 0.996 0.961 1.000 0.911 1.000 0.994 1.000
Dieudé P, 2007 [26S] 3 CT+TT vs.CC 1.08 (1.02–1.15) 8.39 × 10
−3 NA SSc Caucasian NA - 0.999 1.000 0.942 1.000 0.942 1.000 0.997 1.000
Dieudé P, 2007 [26S] 3 CT+TT vs.CC 1.09 (1.04–1.16) 3.11 × 10
−3 NA SSc Overall mixed NA - 0.999 1.000 0.869 1.000 0.869 1.000 0.994 1.000
Psoriasis
Chen YF, 2012 [27S] 10 T vs. C 1.15 (1.00–1.33) <0.05 R Ps Overall mixed 27.8 <0.05 0.717 1.000 0.988 1.000 0.983 1.000 0.998 1.000
Chen YF, 2012 [27S] 5 T vs. C 1.23 (1.00–1.52) <0.05 R Ps Overall mixed 36.4 - 0.410 0.967 0.993 1.000 0.983 1.000 0.998 1.000
Zheng J, 2012 [5S] 4 T vs. C 1.22 (1.02–1.44) 0.023 - Ps Overall mixed - - 0.423 0.993 0.978 1.000 0.950 1.000 0.996 1.000
Ankylosing spondylitis
Meng W, 2017 [28S] 3 TT vs. CC 1.67 (0.39, 7.06) >0.05 F AS Overall mixed 0.00 - 0.327 0.442 0.999 1.000 0.999 1.000 0.999 1.000
Sjögren’s syndrome
Zheng J, 2012 [5S] 2 T vs. C 1.40 (0.91–2.14) 0.01 - SS Overall mixed - - 0.238 0.625 0.998 1.000 0.995 1.000 0.999 1.000
ATA, anti-topoisomerase I antibodies; ACA, anticentromere antibodies; SSc, systemic sclerosis; AS, ankylosing spondylitis; SS, Sjögren’s syndrome; Ps, psoriasis; OR, odds ratio; R, random;
F, fixed; S, supplementary; FPRP, false-positive report probability; BFDP, Bayesian false discovery probability. Each comparison of genetic associations was regarded as noteworthy when
FPRP of <0.2 or BFDP of <0.8 or both are fulfilled and the values were bolded when the results are significant by FPRP or BFDP.
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Table 6. Meta-analysis results of associations between non-rheumatic autoimmune or autoimmunity-related diseases and the PTPN22 1858 C/T polymorphism from
observational studies.
Author, Year No. of
Studies
Comparison OR (95% CI) p-Value Model Disease Ethnicity I2 (%)
Egger’s
p-Value
Power
OR
1.2
Power
OR
1.5
FPRP Values at Prior Probability
BFDP
0.001
BFDP
0.000001OR 1.2 OR 1.5
0.001 0.000001 0.001 0.000001
Vitiligo
Agarwal S, 2017 [29S] 7 T vs. C 1.50 (1.32–1.71) <0.001 F Vitiligo Overall mixed 35.0 - 0.000 0.500 0.003 0.757 0.000 0.003 0.000 0.160
Agarwal S, 2017 [29S] 3 T vs. C 1.53 (1.34–1.75) <0.00001 F Vitiligo European 32.0 - 0.000 0.386 0.003 0.736 0.000 0.001 0.000 0.085
Song GG, 2013 [30S] 5 T vs. C 1.507(1.320–1.720) <1.0 × 10
−8 F Vitiligo Overall mixed <50 >0.05 0.000 0.472 0.003 0.766 0.000 0.003 0.000 0.152
Song GG, 2013 [30S] 4 T vs. C 1.530(1.339–1.748) <1.0 × 10
−8 F Vitiligo European 0<50 >0.05 0.000 0.385 0.002 0.691 0.000 0.001 0.000 0.064
Zheng J, 2012 [5S] 2 T vs. C 1.98 (1.35–2.88) 3.70 × 10−4 - GV Overall mixed - - 0.004 0.073 0.988 1.000 0.828 1.000 0.979 1.000
Crohn’s disease
Hedjoudje A, 2017
[31S] 13 T vs. C 1.28 (1.17–1.4) 8.48 × 10
−8 F CD Overall mixed 37,54 0.48 0.079 1.000 0.001 0.458 0.000 0.063 0.004 0.810
Li X, 2017 [32S] - 0.61 (0.44–0.84) 0.002 R CD Overall mixed 78 - 0.028 0.293 0.989 1.000 0.893 1.000 0.990 1.000
Zheng J, 2012 [5S] 11 T vs. C 0.84 (0.76–0.94) 1.89 × 10−3 - CD Overall mixed - - 0.555 1.000 0.811 1.000 0.704 1.000 0.981 1.000
Diaz-Gallo, 2011 [33S] 12 T vs. C 0.81 (0.75 0.89) 7.4 × 10−6 F CD European NA - 0.277 1.000 0.040 0.977 0.011 0.921 0.325 0.998
Latiano, 2007 [34S] 4 TT+ CT vs.CC 0.77 (0.61–0.97) 0.028 F CD Overall mixed <52 - 0.251 0.889 0.991 1.000 0.968 1.000 0.997 1.000
Inflammatory bowel disease
Li X, 2017 [32S] 10 - 0.71 (0.56–0.90) 0.005 R IBD Overall 81 0.187 0.093 0.699 0.980 1.000 0.869 1.000 0.990 1.000
Myasthenia gravis
Xiong X, 2015 [35S] 7 - 1.57 (1.34–1.82) <0.00001 R MG Overall mixed 31 NA 0.000 0.273 0.012 0.923 0.000 0.008 0.000 0.286
Provenzano C, 2012
[36S] 4 T vs. C 1.56 (1.24–1.95) <1.0 × 10
−4 R MG Overall mixed 14 - 0.011 0.365 0.898 1.000 0.204 0.996 0.856 1.000
Provenzano C, 2012
[36S] 4 T vs. C 1.64 (1.40–1.93) <1.00 × 10
−5 R MG(AChR+) Overall mixed 14 - 0.000 0.141 0.030 0.968 0.000 0.018 0.001 0.386
Provenzano C, 2012
[36S] 4 T vs. C 1.82 (1.44–2.28) <1.00 × 10
−5 R MG(thymoma-) Overall mixed 14 - 0.000 0.046 0.566 0.999 0.004 0.804 0.061 0.985
Zheng J, 2012 [5S] 5 T vs. C 1.53 (1.31–1.80) 1.09 × 10−7 - MG Overall mixed - - 0.002 0.406 0.147 0.994 0.001 0.418 0.031 0.970
Behçet’s disease
Lee YH, 2012 [23S] 3 T vs. C 0.388(0.916–0.770) 0.007 F BD Caucasian 55.9 0.104 0.014 0.061 0.998 1.000 0.991 1.000 0.998 1.000
Lee YH, 2012 [23S] 1 T vs. C 0.37 (0.179–0.765) 0.007 NA BD European NA NA 0.014 0.056 0.998 1.000 0.992 1.000 0.998 1.000
Autoimmune thyroid disease
Luo L, 2012 [37S] 11 TT+TC vs.CC 1.41 (1.12,1.78) 0.07 R AITD Overall mixed - >0.05 0.087 0.699 0.978 1.000 0.846 1.000 0.989 1.000
Luo L, 2012 [37S] 7 TT+TC vs.CC 1.41 (1.09,1.83) 0.03 R AITD Caucasian - >0.05 0.113 0.679 0.989 1.000 0.935 1.000 0.994 1.000
Luo L, 2012 [37S] 4 TT+TC vs.CC 1.01 (0.51,2.00) 0.01 R AITD Others - >0.05 0.690 0.872 0.999 1.000 0.999 1.000 0.999 1.000
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Table 6. Cont.
Author, Year No. of
Studies
Comparison OR (95% CI) p-Value Model Disease Ethnicity I2 (%)
Egger’s
p-Value
Power
OR
1.2
Power
OR
1.5
FPRP Values at Prior Probability
BFDP
0.001
BFDP
0.000001OR 1.2 OR 1.5
0.001 0.000001 0.001 0.000001
Graves’ disease
Luo L, 2012 [37S] 8 TC vs. CC 1.46 (1.12,1.89) 0.07 R GD Overallmixed - >0.05 0.068 0.581 0.983 1.000 0.875 1.000 0.990 1.000
Zheng J, 2012 [5S] 3 T vs. C 1.59 (1.37–1.85) 1.01 × 10−9 - GD Overallmixed - - 0.000 0.225 0.014 0.935 0.000 0.009 0.000 0.281
Lee YH, 2007 [13S] 3 CT vs. CC 1.66 (1.35–2.04) <0.00001 - GD Overallmixed 28.1 - 0.001 0.168 0.586 0.999 0.009 0.896 0.178 0.995
Addison’s disease
Zheng J, 2012 [5S] 6 T vs. C 1.43 (1.21–1.68) 2.36 × 10−5 - AD Overallmixed - - 0.016 0.720 0.451 0.999 0.018 0.950 0.432 0.999
Skinningsrud B, 2008
[38S] 4 T vs. C 1.36 (1.11–1.66) 0.003 - AD European <50 - 0.109 0.832 0.958 1.000 0.750 1.000 0.983 1.000
Roycroft M, 2009 [39S] 5 T vs. C 1.44 (1.21–1.72) 5.6 × 10−5 F AD Caucasian,European 0.00 - 0.022 0.674 0.722 1.000 0.079 0.988 0.738 1.000
Endometriosis
Pabalan N, 2017 [40S] 10 Co-dominant 3.14 (1.93–5.10) <0.001 - Endometriosis Overallmixed 86.0 - 0.000 0.001 0.987 1.000 0.727 1.000 0.941 1.000
Pabalan N, 2017 [40S] 9 Co-dominant 3.08 (1.84–5.14) <0.001 - Endometriosis(HWE only)
Overall
mixed 88.0 - 0.000 0.003 0.991 1.000 0.850 1.000 0.973 1.000
Pabalan N, 2017 [40S] 8 Co-dominant 3.86 (2.40–6.21) <0.001 - Endometriosis Italian 78.0 - 0.000 0.000 0.972 1.000 0.346 0.998 0.658 0.999
Alopecia areata
Zheng J, 2012 [5S] 2 T vs. C 1.38 (1.11–1.72) 0.003 - AA Overallmixed - - 0.107 0.771 0.975 1.000 0.843 1.000 0.989 1.000
GV, generalized vitiligo; BD, Behçet’s disease; IBD, inflammatory bowel disease; AD, Addison’s disease; MG, myasthenia gravis; GD, Graves’ disease; Crohn’s disease; AITD, autoimmune
thyroid disease; AA, alopecia areata; OR, odds ratio; R, random; F, fixed; S, supplementary; FPRP, false-positive report probability; BFDP, Bayesian false discovery probability. Each
comparison of genetic associations was regarded as noteworthy when FPRP of <0.2 or BFDP of <0.8 or both are fulfilled and the values were bolded when the results are significant by
FPRP or BFDP.
J. Clin. Med. 2019, 8, 347 13 of 22
Table 7. Meta-analysis results of associations between type 1 diabetes mellitus (T1DM) and the PTPN22 1858 C/T polymorphism from observational studies.
Author, Year No. of
Studies
Comparison OR (95% CI) p-Value Model Disease Ethnicity I2 (%)
Egger’s
p-Value
Power
OR
1.2
Power
OR
1.5
FPRP Values at Prior Probability
BFDP
0.001
BFDP
0.000001OR 1.2 OR 1.5
0.001 0.000001 0.001 0.000001
Ramu D, 2018 [41S] 16 TT vs. CC 2.67 (1.92–3.70) <0.0001 F T1DM(LADA)
Overall
mixed 24.8 - 0.000 0.000 0.824 1.000 0.013 0.932 0.040 0.976
Dong F, 2014 [42S] 5 T vs. C 1.52 (1.29–1.79) <0.001 F T1DM(LADA)
Overall
mixed 12.14 0.54 0.002 0.437 0.184 0.996 0.001 0.543 0.050 0.981
Xuan C, 2013 [43S] 28 CT+TT vs. CC 1.957(1.817–2.108) 2.94 × 10
−70 F T1DM Overallmixed 36.7 0.544 NA NA NA NA NA NA 0.000 0.000
Xuan C, 2013 [43S] 27 CT+TT vs. CC 1.962(1.821–2.113) 2.46 × 10
−70 R T1DM Caucasian 37.5 0.320 NA NA NA NA NA NA 0.000 0.000
Xuan C, 2013 [43S] 7 CT+TT vs. CC 1.96 (1.806–2.127) 1.85 × 10−58 F T1DM(Male) Caucasian 0.00 0.548 NA NA NA NA NA NA 0.000 0.000
Xuan C, 2013 [43S] 7 TT vs. CC 3.537(2.704–4.625) 2.71 × 10
−20 F T1DM(Female) Caucasian 31.8 0.764 NA NA NA NA NA NA 0.000 0.000
Wang X F, 2013 [44S] 34 Recessive 2.78 (2.25–3.44) <1.0 × 10−5 R T1DM Overallmixed NA NA NA NA NA NA NA NA 0.000 0.000
Wang XF, 2013 [44S] 23 Recessive 3.42 (2.55–4.59) <1.0 × 10−5 R T1DM (<500) Overallmixed NA NA 0.000 0.000 0.106 0.992 0.000 0.009 0.000 0.000
Wang XF, 2013 [44S] 8 Recessive 2.27 (1.71–3.01) <1.0 × 10−5 R T1DM(500~1000)
Overall
mixed NA NA 0.000 0.002 0.722 1.000 0.006 0.861 0.031 0.969
Wang XF, 2013 [44S] 3 Recessive 2.26 (1.57–3.25) <1.0 × 10−5 R T1DM(>1000)
Overall
mixed NA NA 0.000 0.014 0.972 1.000 0.446 0.999 0.875 1.000
Wang XF, 2013 [44S] 8 allelic 1.80 (1.36–6.55) <1.0 × 10−5 R T1DM (Male) Overallmixed NA NA 0.269 0.391 0.999 1.000 0.999 1.000 0.999 1.000
Wang XF, 2013 [44S] 8 allic 8.26 (3.05–22.38) <1.0 × 10−5 R T1DM(Female)
Overall
mixed NA NA 0.000 0.000 0.998 1.000 0.988 1.000 0.997 1.000
Wang XF, 2013 [44S] 20 Recessive 2.57 (2.00–3.32) <1.0 × 10−5 R T1DM (Early) Overallmixed NA NA 0.000 0.000 0.153 0.994 0.000 0.026 0.000 0.015
Wang XF, 2013 [28S] 8 Recessive 5.86 (3.40–10.12) <1.0 × 10−5 R T1DM (Late) Overallmixed NA NA 0.000 0.000 0.972 1.000 0.307 0.998 0.495 0.999
Tang S, 2012 [45S] 24 CC vs. CT 0.532(0.467–0.595) <0.001 R T1DM
Overall
mixed 38.47 0.695 NA NA NA NA NA NA 0.000 0.000
Tang S, 2012 [45S] 18 CC vs. CT 0.532(0.467–0.606) <0.05 - T1DM Europe NA >0.05 NA NA NA NA NA NA 0.000 0.000
Tang S, 2012 [45S] 4 CC vs. CT 0.526(0.434–0.636) <0.05 - T1DM America NA >0.05 0.000 0.007 0.032 0.970 0.000 0.005 0.000 0.034
Peng H, 2012 [46S] 24 TT+TC vs. CC 1.988(1.832–2.157) <0.001 R T1DM
Overall
mixed 34.8 0.560 NA NA NA NA NA NA 0.000 0.000
Peng H, 2012 [46S] 19 TT+TC vs. CC 1.976(1.801–2.169) <0.001 R T1DM European 40.2 0.355 NA NA NA NA NA NA 0.000 0.000
Peng H, 2012 [46S] 5 TT+TC vs. CC 2.017 (1.727,2.355) <0.001 F T1DM American 14.0 0.486 NA NA NA NA NA NA 0.000 0.000
Zheng J, 2012 [5S] 23 T vs. C 1.84 (1.72–1.96) <1.0 × 10−16 - T1DM Overallmixed - - NA NA NA NA NA NA 0.000 0.000
Lee YH, 2007 [13S] 6 TTvs.CC 3.56 (2.39–5.31) <0.00001 - T1DM Overallmixed 0.00 - 0.000 0.000 0.908 1.000 0.041 0.977 0.072 0.987
T1DM, type 1 diabetes mellitus; LADA, latent autoimmune diabetes in adults; OR, odds ratio; R, random; F, fixed; S, supplementary; FPRP, false-positive report probability; BFDP, Bayesian
false discovery probability. Each comparison of genetic associations was regarded as noteworthy when FPRP of <0.2 or BFDP of <0.8 or both are fulfilled and the values were bolded when
the results are significant by FPRP or BFDP. NAs are expressed when information is not available by FPRP calculations.
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Table 8. Meta-analysis results of gene variants from genome-wide association studies showing significant p-value (<5 × 10−8).
Author, Year No. of
Studies
Comparison OR (95% CI) p-Value Model Disease Ethnicity I2 (%)
Power
OR 1.2
Power
OR 1.5
FPRP Values at Prior Probability
BFDP
0.001
BFDP
0.000001OR 1.2 OR 1.5
0.001 0.000001 0.001 0.000001
Bowes J, 2014 [47S] 4 T vs. C 1.32 (1.21–1.45) 1.49 × 10−9 - PsA Caucasian 0.023 0.996 0.000 0.228 0.000 0.007 0.023 0.001 0.349
Gregersen PK, 2012
[48S] 3 T vs. C 1.71 (1.44–2.02) 3.72 × 10
−10 - MG NorthEuropean 0.000 0.062 0.018 0.947 0.000 0.004 0.000 0.000 0.095
Thompson SD, 2010
[49S] 2 additive 1.64 (1.44–1.87) 1.90 × 10
−13 - JIA Initial +Replication 0.000 0.091 0.000 0.088 0.000 0.000 0.000 0.000 0.000
Coenen MJ, 2009 [50S] 2 T vs. C 1.67 (1.52–1.84) 2.0 × 10−27 R RA
Caucasian
European(miao)
(Dutch+ UK)
NA NA NA NA NA NA NA 0.000 0.000
RA, rheumatoid arthritis; PsA, psoriatic arthritis; MG, myasthenia gravis; JIA, juvenile idiopathic arthritis; OR, odds ratio; R, random; S, supplementary; FPRP, false-positive report
probability; BFDP, Bayesian false discovery probability. Each comparison of genetic associations was regarded as noteworthy when FPRP of <0.2 or BFDP of <0.8 or both are fulfilled and
the values were bolded when the results are significant by FPRP or BFDP. NAs are expressed when information is not available by FPRP calculations.
Table 9. Meta-analysis results of the PTPN22 1858 C/T polymorphism from genome wide association studies showing significant p-value (5 × 10−8 < p< 0.05).
Author, Year NO. of
studies
Comparison OR (95% CI) p-Value Model Disease Ethnicity I2 (%)
Power
OR 1.2
Power
OR 1.5
FPRP Values at Prior Probability
BFDP
0.001
BFDP
0.000001OR 1.2 OR 1.5
0.001 0.000001 0.001 0.000001
Merkel PA, 2017 [51S] 3 T vs. C 1.36 (1.21–1.53) 1.86 × 10−7 - ANCA
Overall
European
ancestry
0.019 0.948 0.016 0.943 0.000 0.247 0.019 0.020 0.953
Törn C, 2015 [52S] 3 T vs. C 2.42 (1.70–3.44) 1.01 × 10−6 - T1DMvs. Ab-
Caucasian
children 0.000 0.004 0.948 1,000 0.180 0.995 0.000 0.601 0.999
Serrano A, 2013 4 T vs. C 1.51 (1.28–1.79) 2.0 × 10−6 F GCA Caucasian 0.004 0.469 0.336 0.998 0.004 0.814 0.004 0.151 0.994
Thompson SD, 2010
[53S] 3 Recessive 1.63 (1.35–1.97) 3.12 × 10
−7 - JIA Germany+Texas +Utah 0.001 0.195 0.360 0.998 0.002 0.689 0.001 0.062 0.985
GCA, giant cell arteritis; PsA, psoriatic arthritis; JIA, juvenile idiopathic arthritis; RA, rheumatoid arthritis; ANCA, antineutrophil cytoplasmic antibody; GPA, granulomatosis with
polyangiitis; MPA, microscopic polyangiitis; PR3, proteinase 3; cANCA, cytoplasmic ANCA; MPO, myeloperoxidase; pANCA, perinuclear ANCA; MG, myasthenia gravis; OR, odds ratio;
R, random; FPRP, false-positive report probability; BFDP, Bayesian false discovery probability. Each comparison of genetic associations was regarded as noteworthy when FPRP of <0.2 or
BFDP of <0.8 or both are fulfilled and the values were bolded when the results are significant by FPRP or BFDP.
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2.4. Statistical Analysis
To verify the noteworthiness of the reported genetic association, we used the Bayesian approaches,
FPRP and BFDP. In our study, noteworthiness was used as a term that a genetic association of PTPN22
is associated with a disease in a significant manner. FPRP, proposed by Wacholder et al., tests the
probability of no true association between the polymorphism and the disease [10]. FPRP can be
derived from the following equation: FPRP = α (1 − pi)/{α (1 − pi) + (1 − β)} in which (1) pi (the prior
probability of a true association), (2) the lowest α where the test is noteworthy or the observed p-value,
and (3) 1 − β (the statistical power at which the finding is defined as noteworthy) [11].
We used two pre-specified values for prior probabilities (10−3 and 10−6) and two values of OR
(1.2, 1.5) which were thought to be valid for a noteworthy finding were chosen. FPRP was calculated
by an Excel spreadsheet reported by Wacholder et al. [10] and a FPRP value less than 0.2 was regarded
as noteworthy genetic association.
Secondly, BFDP, newly proposed by Wakefield et al. [12], also clarifies the noteworthiness of the
reported genetic association. It provides a description of a noteworthiness by means of the cost of a
false discovery and a false non-discovery, while utilizing more information than FPRP [12]. According
to the literature, the cutoff level for BFDP is set at 0.8, derived from the assumption that a false
non-discovery is four times as costly as a false discovery. BFDP can also be calculated by the following
equation and an Excel spreadsheet was reported by Wakefield et al. [12], where PO is the prior odds of
no association and ABF is the approximate Bayes factor which can be deduced from OR and SE.
BFDP = (ABF × PO)/(ABF × PO + 1)
We also used two pre-specified values for prior probabilities (10−3 and 10−6) and a BFDP value
less than 0.8 was noteworthy. Each comparison of the genetic associations was regarded as noteworthy
when FPRP of <0.2 or BFDP of <0.8 or both were fulfilled. We adopted these cut-offs of FPRP
and BFDP, because these were set by the original authors (Wacholder et al. and Wakefield et al.,
respectively) [10,12].
All the calculations to derive FPRP and BFDP were performed with the Excel spreadsheet released
by Wacholder et al. and Wakefield et al. [10,12]. The values for FPRP and BFDP of the observational
studies were specified in Tables 1–7. Results for GWAS were separately described in Tables 8 and 9
depending on whether p-value was adequately significant (p < 5 × 10−8) or was situated on the
boundary of statistical significance (0.05 < p < 5 × 10−8).
3. Results
The genetic association of the PTPN22 1858 C/T variant was evaluated in a total of 20 autoimmune
or autoimmunity-related diseases. Most studies focused on rheumatoid arthritis (RA, n = 13), systemic
lupus erythematosus (SLE, n = 7) and type 1 diabetes mellitus (T1DM, n = 8), followed by five on
juvenile idiopathic arthritis (JIA), 5 on Crohn’s disease (CD), 4 on anti-neutrophil cytoplasmic antibody
(ANCA)-associated vasculitis, 3 on vitiligo, 3 on systemic sclerosis (SSc), 3 on Graves’ disease (GD),
3 on myasthenia gravis (MG), 3 on Addison’s disease (AD), 2 on psoriasis, 1 study on Behcet’s disease
(BD), 1 on endometriosis, 1 on autoimmune thyroid disease (AITD), 1 on inflammatory bowel disease
(IBD), 1 on giant cell arteritis (GCA), 1 on alopecia areata (AA), 1 on Sjögren’s syndrome (SS), and 1
study on ankylosing spondylitis (AS).
In observational studies, the associations of 1858 C/T genetic variant were noteworthy for 12
autoimmune or autoimmunity-related diseases (RA, T1DM, SLE, JIA, CD, ANCA-associated vasculitis,
vitiligo, GD, MG, AD, GCA, and endometriosis). In contrast, the results did not show noteworthiness
for eight diseases (SSc, psoriasis, BD, AITD, AA, SS, IBD and AS).
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3.1. Rheumatoid Arthritis
A total of 13 observational studies with 39 genotypes and allelic comparisons were included.
Most studies used the general population as the comparators. Out of 39 RA comparisons, 10 and 4
were verified to be noteworthy (<0.2) using the FPRP estimation, at a prior probability of 10−3 and
10−6 with a statistical power to detect an OR of 1.2. In addition, 13 and 11 comparisons were verified
to be noteworthy at a prior probability of 10−3 and 10−6 with a statistical power to detect an OR of 1.5.
With the use of BFDP, 32 and 30 comparisons showed noteworthiness at a prior probability of 10−3
and 10−6, respectively. In total, 32 (82.1%) of the 39 comparisons had noteworthy findings by FPRP or
BFDP (Table 1).
3.2. Juvenile Idiopathic Arthritis
Five studies with 15 genotype and allele comparisons were included. By means of FPRP
estimation, 5 and 3 findings were noteworthy at a prior probability of 10−3 and 10−6 with a statistical
power to detect an OR of 1.2, respectively. Moreover, 7 and 4 were noteworthy at a prior probability of
10−3 and 10−6 with a statistical power to detect an OR of 1.5, respectively. In terms of BFDP estimation,
8 and 6 comparisons showed worthiness at a prior probability of 10−3 and 10−6, respectively. In total,
9 (60%) of the 15 comparisons had noteworthy findings by FPRP or BFDP (Table 2).
3.3. Systemic Lupus Erythematosus
Seven observational studies with 15 genotypes and allelic comparisons were identified. Out of 15
comparisons, 8 and 3 were noteworthy using FPRP estimation, at a prior probability of 10−3 and 10−6
with a statistical power to detect an OR of 1.2. In addition, 11 and 6 showed noteworthiness at a prior
probability of 10−3 and 10−6 with a statistical power to detect an OR of 1.5. In terms of BFDP, 13 and 8
comparisons had noteworthy findings at a prior probability of 10−3 and 10−6 (Table 3). In total, 13
(86.7%) of the 15 comparisons had noteworthy findings by FPRP or BFDP.
3.4. Vasculitides
A total of 4 studies with 11 genotypes and allelic comparisons were included for ANCA-associated
vasculitis. Out of 11 comparisons, 3 were noteworthy using FPRP estimation, at a prior probability of
10−3 with a statistical power to detect an OR of 1.2. In addition, 6 and 2 were verified to be noteworthy
at a prior probability of 10−3 and 10−6 with a statistical power to detect an OR of 1.5 by FPRP. In
terms of BFDP, 6 and 2 comparisons had noteworthy findings at a prior probability of 10−3 and 10−6,
respectively (Table 4). In total, 6 (54.5%) of the 11 comparisons had noteworthy findings by FPRP
or BFDP.
For the studies including subjects with GCA, only one study with three allelic comparisons was
included. Two comparisons verified noteworthiness at a prior probability of 10−3 with a statistical
power to detect an OR of 1.5. By using BFDP, two results were noteworthy at a prior probability of
10−3 (Table 4).
3.5. Other Rheumatic Autoimmune Diseases
Two studies with three allelic comparisons analyzed the genetic impact of psoriasis and did not
verify noteworthiness by means of both FPRP and BFDP estimations (Table 5). Three studies including
patients with SSc analyzed 7 genotypes and allelic comparisons. Findings did not show noteworthiness
in terms of FPRP and BFDP estimations (Table 5). Two studies examined associations of psoriasis
and only one study was available for each SS and AS. Findings from these diseases did not verify
noteworthiness by means of FPRP and BFDP estimations (Table 5).
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3.6. Other Autoimmune or Other Disorders
Three studies with 5 comparisons were included from patients with vitiligo. In terms of FPRP
estimation, 4 results were only noteworthy at a prior probability of 10−3 with a statistical power to
detect an OR of 1.2. In addition, four results were noteworthy at a prior probability of 10−3 and 10−6
with a statistical power to detect an OR of 1.5. Using BFDP estimation, findings were noteworthy
except for generalized vitiligo which did not show any noteworthiness by using both FPRP and BFDP
estimations (Table 6). In total, 4 (80%) of the 5 comparisons had noteworthy findings by FPRP or BFDP.
Five studies including patients with CD had five comparisons. In terms of FPRP, two findings
were noteworthy at a prior probability of 10−3 with a statistical power to detect an OR of 1.2. Moreover,
noteworthiness was reported for 2 results and 1 result at a prior probability of 10−3 and 10−6,
respectively, with a statistical power to detect an OR of 1.5, respectively. By using BFDP estimation, only
2 results were noteworthy at a prior probability of 10−3 (Table 6). In total, 2 (40%) of the 5 comparisons
had noteworthy findings by FPRP or BFDP.
Three studies reporting five allelic comparisons were included from subjects with MG. Out
of 5 comparisons, 3 findings were noteworthy, by using FPRP, at a prior probability of 10−3 with
a statistical power to detect an OR of 1.2. In addition, 4 and 2 verified noteworthiness at a prior
probability of 10−3 and 10−6 with a statistical power to detect an OR of 1.5. In terms of BFDP, 4 and
2 results were noteworthy at a prior probability of 10−3 and 10−6, respectively (Table 6). In total,
4 (80%) of the 5 comparisons had noteworthy findings by FPRP or BFDP. In addition, there were no
noteworthy findings by FPRP or BFDP in one study (2 comparisons) of Behçet’s disease and one study
(3 comparisons) of AITD.
Three studies with 3 allelic comparisons were included for Addison’s disease. Out of the three
comparisons, 2 were noteworthy at a prior probability of 10−3 with a statistical power to detect an OR
of 1.5. In terms of BFDP, 2 findings verified noteworthiness at a prior probability of 10−3. For patients
with endometriosis, one study with three co-dominant comparisons did not verify noteworthiness,
except for one finding which was noteworthy by using BFDP at a prior probability of 10−3. There were
no noteworthy findings by FPRP or BFDP in one study (1 comparison) of alopecia areata (Table 6).
3.7. Type 1 Diabetes Mellitus
Regarding the association of PTPN22 and T1DM, 8 studies with 22 comparisons were included
in the analysis. Out of 22 comparisons, 4 verified noteworthiness using FPRP estimation, at a prior
probability of 10−3 with a statistical power to detect an OR of 1.2. In addition, 7 and 3 comparisons
were noteworthy at a prior probability of 10−3 and 10−6 with a statistical power to detect an OR of
1.5, respectively. By using BFDP estimation, 19 and 14 findings were noteworthy at a prior probability
of 10−3 and 10−6, respectively (Table 7). In total, 19 (86.4%) of the 22 comparisons had noteworthy
findings by FPRP or BFDP.
3.8. Meta-Analysis of Genome-Wide Association Studies
Among the included GWAS meta-analyses, findings verified noteworthiness for all included
diseases. Four studies with a p-value <5× 10−8 showed noteworthiness by FPRP or BFDP for PsA, MG,
RA and JIA. All comparisons were based on Caucasian populations. Out of four genotype and allelic
comparisons, three were verified to be noteworthy (<0.2) using FPRP estimation, at a prior probability
of 10−6 with a statistical power to detect an OR of 1.2 and 1.5. By means of BFDP, the four comparisons
had noteworthy findings (<0.8) at a prior probability of 10−3 and 10−6 (Table 8). In four studies with a
non-significant GWAS p-value (5 × 10−8 < p < 0.05), findings were noteworthy for ANCA-associated
vasculitis, T1DM, GCA and JIA. The four comparisons were verified to be noteworthy using FPRP
estimation, at a prior probability of 10−6 with a statistical power to detect an OR of 1.2 and 1.5. In terms
of BFDP, results were noteworthy at a prior probability of 10−3 (Table 9).
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In addition, we were unable to estimate noteworthiness of 32 potential associations under FPRP
due to a mathematical error while performing a calculation using excel. It was considered that a
substantially low p-value with a narrow CI hindered the computation for obtaining the inverse of the
cumulative normal distribution.
4. Discussion
The current work is a comprehensive search of the literature which outnumbers previous
meta-analyses focusing on the association of PTPN22 1858 C/T polymorphism and autoimmune
diseases and is the first work applying Bayesian procedures such as FPRP and BFDP to prove the
noteworthiness of such associations.
We describe the results of genotype associations that were found to be noteworthy through FPRP
and BFDP estimations and these Bayesian statistical methods were useful to detect true noteworthiness
(genuine associations) for the genetic associations between the gene variant and disease. In recent years,
Bayesian methods have been increasingly used because of their extreme flexibility as a major advantage.
Bayesian methods can provide researchers with gains in performance of statistical estimation by
incorporating prior information. BFDP allows the calculation of the recently proposed FPRP but uses
more information [10,12]. These methods were introduced as criteria, “to help investigators, editors,
and readers of research articles to protect themselves from over interpreting statistically significant
findings that are not likely to signify a true association” [12].
In observational studies, the associations of the 1858 C/T genetic variant were noteworthy
for 12 autoimmune or autoimmunity-related diseases (RA, T1DM, SLE, JIA, CD, ANCA-associated
vasculitis, vitiligo, GD, MG, AD, GCA, and endometriosis) and the positive rate of true noteworthiness
was different among diseases. The role of the pleiotropic 1858C/T of PTPN22 may suggest common
and shared immune functions in various autoimmune diseases. More functional studies in the future
may identify specific effects of this polymorphism in each autoimmune disease.
However, the results did not show noteworthiness for the remainder, highlighting the need
for further investigations. The non-significant association may implicate that the functional effect of
C1858T on the Lyp protein is not a major contributing factor to study these autoimmune diseases or that
the pathogenic inflammatory responses are not influenced or regulated by this pathway. In addition,
the non-synonymous C1858T genetic variant is the only significant SNP out of many within the
PTPN22 region, but we suggest that some other synonymous variants in these pathologies should be
studied more intensively to elucidate their function. Furthermore, genetic association studies should
be replicated in different populations with larger sizes.
All GWAS findings verified noteworthiness for all included diseases. Four studies with a p-value
<5 × 10−8 showed noteworthiness for PsA, MG, RA and JIA. Noteworthiness showing an association
of four autoimmune diseases, namely ANCA-associated vasculitis, T1DM, GCA and JIA, could be
observed in the GWAS non-significant findings when a p-value ranged between 5 × 10−8 and 0.05.
It can be assumed that GWAS produces a more solid evidence than observational studies with a lower
amount of false positive results, because of its stringent threshold to determine a significance. However,
other genetic variants had a significant p-value (i.e., p < 0.05 for observational studies and p < 5 × 10−8
for GWAS) and found noteworthy by our Bayesian approaches and thus it may be concluded that
results from GWAS with a p-value < 5 × 10−8could be identically replicated in observational studies.
Some comparisons that could not be calculated using FPRP (either due to missing reports of upper
and lower confidence intervals or a mathematical error in the process of calculating the inverse of the
cumulative normal distribution) could be computed using BFDP and were found to be noteworthy in
our final analysis.
PTPN22 encodes a protein tyrosine phosphatase that inhibits antigen-receptor signaling in T
cells and promotes pattern-recognition receptor-induced type I interferon production by myeloid
cells. Zheng et al. [14] proposed that PTPN22 has stronger associations with autoimmune disorders
in which auto-antibodies have a major role in pathogenesis. The effect of PTPN22 depends on the
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respective tissue affected by autoimmunity [14]. Autoimmune diseases affecting connective tissues,
joints, muscles, blood, pancreas, kidney or thyroid show a stronger association with PTPN22 than
diseases of the gastrointestinal tract or immune-privileged sites, such as the central nervous system
and the eye [14]. Genetic mutation plays an important role in the development of autoimmune
disease. The PTPN22 1858T variant was among the first SNPs to be associated with multiple
autoimmune diseases. Autoimmunity, promoted by PTPN22 1858C/T, involves the differentiation
of T-cell subsets, the B-cell repertoire and balance between immunoregulatory and proinflammatory
cytokine production [15]. Current studies highlight a role of 1858 C/T polymorphism in autoimmunity
by altering innate and adaptive immune responses. Thus, studies of human cells demonstrate the
impact of the1858 C/T polymorphism on both maturation and function of hematopoietic lineages,
each potentially contributing to autoimmunity [16]. In human lymphocytes, the SNP disrupts the
interaction between PTPN22 and Csk [2,17]. The interaction with Csk modulates the inhibitory function
of PTPN22 in TCR signaling [17,18]. Considering that some of the strongest associations of the PTPN22
1858C/T are with autoimmune diseases characterized by the production of circulating autoantibodies,
dysregulation of B-cell clonal deletion and receptor editing is likely to contribute to PTPN22-associated
autoimmune diseases [19]. Previous studies demonstrated a decrease in IL-2 production after TCR
stimulation in patients with T1DM carrying the PTPN22 1858T variant [20]. Analysis of individuals
with the variant allele and ANCA-associated vasculitis showed a decrease in IL-10 production, which
is known to exhibit anti-inflammatory properties [21]. The 1858 C/T polymorphism has also been
shown to impair production of type I interferons by myeloid cells [22]. Other SNPs of PTPN22 have
been associated with connective tissue diseases. PTPN22 788G>A is a rare missense SNP that does
not show co-occurrence with PTPN22 1858C>T [23]. PTPN22 788G>A encodes a loss-of-function
Arg263Gln substitution in the PTPN22 catalytic domain, which changes the conformation of the active
site and reduces the phosphatase activity of the protein [23]. It has been suggested that the 1858C/T
polymorphism is selected in co-evolution with the increase of autoimmune diseases in modern societies.
Therefore, the 1858C/T polymorphism is variable in allele frequency across different ethnic groups.
There is a noticeable decrease in minor T allele frequencies in Caucasians from northern Europe to
southern Europe [24,25]. The highest minor allele frequencies have been reported from Scandinavian
countries [26,27], and the lowest minor allele frequency has been observed in Italy [2]. Minor allele
frequency of the T allele in US Caucasians ranges from 7% to 9% [28]. In non-Caucasian populations,
the 1858 C/T polymorphism is substantially less polymorphic. In fact, this polymorphism has not
been found in African or Asian populations [29,30].
Although our report is the most updated and most analytical summary of available evidences on
1858 C/T polymorphism in autoimmune diseases, the review has some limitations. First, it should be
noted that the lack of association might reflect the limited power of the studies including only a small
number of patients with rare diseases. Secondly, we only included a single result of meta-analysis
with the lowest p-value per disease. Therefore, we could not consider other factors such as statistical
models (i.e., random or fixed), ethnicity, and type of genotype comparison (i.e., recessive, dominant,
additive, co-dominant). In addition, despite our efforts, (1) some relevant articles may not have been
included based on our search criteria as we considered publications limited to the PubMed database
only; (2) some observational studies have been used for more than one meta-analysis, which raises the
statistical issue of type 1 error inflation; and (3) we have not considered papers dealing with various
permutations and interactions with other genes. Moreover, very few observational studies and GWAS
involved African, Middle Eastern, and Asian populations and a population stratification analysis
based on the same ethnic and geographic population may require further investigation.
In addition, FPRP often generates much smaller posterior null estimates than BFPD, because FPRP
is a lower bound on the posterior probability relevant to the observed estimates [10,12]. However, both
approaches may be a beneficial method to distinguish whether the reported associations were genuine
or not, especially for interpreting the retrieved results from observational studies, as shown in other
previous reports [31–35].
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5. Conclusions
We attempted to synthesize all meta-analyses on genetic associations of the PTPN22 1858 C>T
polymorphism with autoimmune diseases and investigated their validity to discover false positive
results under Bayesian methods. To verify results obtained from genetic analyses, both approaches
may have advantages, and we were able to confirm significance in almost all autoimmune diseases
within this borderline significance range. Therefore, PTPN22 is further confirmed as a candidate gene
for further studies. Its promiscuous association with multiple autoimmune diseases might indicate
a common mechanism underlying the development of autoimmune disease. Such a finding would
have huge implications in our current understanding of autoimmunity and may be of therapeutic
benefit and aid in devising preventative strategies. In addition, further studies should be performed to
elucidate how PTPN22 1858 C/T could influence the pathogenesis of each autoimmune disease.
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